ARTICLE | Company News
Mylan expecting another delay for generic Advair
June 14, 2018 10:40 PM UTC
Mylan N.V. (NASDAQ:MYL) said it expects to receive a second complete response letter from FDA for an ANDA of a generic version of Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK).
Any delay would be a reprieve for GSK, which reported worldwide Advair sales of £3.1 billion ($4.2 billion), including U.S. sales of £1.6B ($2.2 billion), last year. ...
BCIQ Target Profiles